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Sensitivity and specificity of diagnostic
tests for Lassa fever: a systematic review
Noah Fongwen Takah1,3*, Polina Brangel2, Priyanka Shrestha3 and Rosanna Peeling3
Abstract
Background: Lassa fever virus has been enlisted as a priority pathogen of epidemic potential by the World Health
organization Research and Development (WHO R & D) Blueprint. Diagnostics play a crucial role in epidemic
preparedness. This systematic review was conducted to determine the sensitivity and specificity of Lassa fever
diagnostic tests for humans.
Methods: We searched OVID Medline, OVID Embase, Scopus and Web of Science for laboratory based and field
studies that reported the performance of diagnostic tests for Lassa fever in humans from 1 January 1990 to 25
January 2019. Two reviewers independently screened all the studies and included only studies that involved the
evaluation of a Lassa fever diagnostic test and provided data on the sensitivity and specificity. The quality of the
studies was assessed using the QUADAS-2 criteria. Data on the study location, study design, type of sample, index
test, reference tests and diagnostic performance were extracted from the studies.
Results: Out of a total of 1947 records identified, 1245 non-duplicate citations were obtained. Twenty-six (26) full-text
articles examined which identified 08 studies meeting pre-defined criteria. Only one study was a field evaluation study.
The sensitivity and specificity of the point of care (RDT) against the Nikisins qPCR were 91.2%(95% CI:75.2–97.7) and
86%(95% CI: 71.4–94.2) at temperatures 18–30 °C, while the sensitivity and specificity of the single IgM ELISA assay
against standard RT-PCR were 31.1%(95%CI: 25.6–37) and 95.7%(95%CI:92.8–97.7). The sensitivity of the combined ELISA
Antigen/IgM assay(against virus isolation), the recombinant IgM/IgG ELISA(against standard RT-PCR), and the IgM/IgG
immunoblot(against IFA) were 88%(95%CI:77–95), 25.9%(95%CI:20.8–31.6), and 90.7%(95%CI:84.13–97.27) respectively.
The specificity of the combined ELISA Antigen/IgM assay(against virus isolation), the recombinant IgM/IgG
ELISA(against standard RT-PCR), and the IgM/IgG immunoblot(against IFA) were 90%(95%CI:88–91),
100%(95%CI:98.2–100), and 96.3%(95%CI:92.2–100) respectively.
Conclusion: Lassa fever has assays for antigenaemia, IgM, IgG and PCR detection. The RDT reportedly performed well but
more data are needed from other countries and at temperatures above 30 °C. Most combined immunoassays perform
better than the single IgM. Multiplex and pan-Lassa assays are needed. More well conducted field studies are needed.
Trial registration: Prospero registration number: CRD42018091585.
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Background
Lassa fever is an acute and potentially fatal hemorrhagic
illness caused by the Lassa Fever Virus [1]. The disease
has been shown to be endemic in several West African
countries including Benin, Guinea, Liberia, Côte d’Ivoire,
Mali, Nigeria, and Sierra Leone [2]. The disease is also
important in global health security as reflected in the in-
clusion of the Lassa fever virus in the World Health
Organization Research and Development (WHO R&D)
Blueprint as a priority pathogen of epidemic potential
[3]. Studies have reported the number of clinical infec-
tions to be approximately 100,000–300,000 in West Af-
rica per year, with approximately 5000 deaths [4, 5]. The
recent outbreak of the Lassa epidemic in Nigeria re-
sulted in 327 cases of Lassa fever (324 confirmed and
three probable cases) with 72 deaths (case fatality ratio
of 22%) from 1 January to 10 February 2019. The WHO
estimates a Lassa case fatality rate of 1, and 15%
amongst patients hospitalized with severe illness [6].
Lassa fever is a zoonotic infection that can be trans-
mitted to humans through contact with virus-infected
rodent excreta via eating rodent-contaminated food, ex-
posure to contaminated objects, and inhalation of tiny
particles in the air contaminated with virus-infected ro-
dent excretions [7]. Though not widely observed in epi-
demic outbreaks, human-to-human transmission can
also occur through contact with fluids of infected per-
sons in health care settings through poor infection con-
trol measures [8]. Diagnostics play a pivotal role in the
control of an outbreak of Lassa fever by: permitting early
diagnosis which can necessitate prompt antiviral therapy
and reduce morbidity and mortality; assisting in the
tracking of community contacts as well as providing the
true picture of the epidemic [9–11].
Despite the relevance of diagnostics in the response to
Lassa fever outbreaks, the availability of Lassa fever diag-
nostics is limited for several reasons. Clinically, most Lassa
fever patients are asymptomatic, and even when symp-
toms are present, they can be non-specific [12]. There are
also enormous challenges faced in developing an effica-
cious assay due to the complexity of the Lassa virus se-
quence diversity [13]. Furthermore, the collection, storage
and handling of specimens for Lassa fever requires bio-
safety level precautions similar to the Ebola virus (Ref).
The need for high containment safety requirements and
the scarcity of high containment laboratories in many
parts of the World may have led to limited Lassa fever
assay development and validation studies [14]. However,
with the World Health Organization (WHO) call for early
diagnostic tests for Lassa [15] and the inclusion of Lassa
fever virus as a priority pathogen of epidemic potential in
the WHO Research and Development (WHO R &D) [3,
5], it is necessary to systematically review all the diagnostic
tests available, so that gaps in diagnostic research and
development can be identified that can guide innovation
in R & D.
Raabe and Koehler conducted a minireview that pro-
vides an overview of the currently available diagnostic
tests for Lassa [14]. Given that it was minireview, it was
clear that the search was not systematic with no quality
assessment of the included studies. In addition, the re-
view doesn’t provide complete data on the sensitivity
and specificity of the diagnostic tests used. Based on the
scarcity of systematic reviews with regards to Lassa diag-
nostics, we conducted this systematic review to deter-
mine the sensitivity and specificity of tests available for
the diagnosis of Lassa fever in humans. This study will
be important in identifying the weaknesses, strengths
and applications of the diagnostic assays available for
Lassa fever.
Methods
Search strategy and identification of studies
This was a systematic review of the diagnostic accur-
acy of Lassa fever tests used for humans. The review
was registered in PROSPERO (Registration number:
CRD42018091585) [16] and reported in accordance
with the Preferred Reporting Items for Systematic Re-
views and Meta-analyses (PRISMA) check list [17].
Literature search strategies were developed by two re-
viewers (NFT and PB) with the help of a librarian at
the London School of Hygiene and Tropical Medicine
with expertise in systematic review searching. The
search strategies are shown in Additional file 1: Table
S1 and Additional file 2: Table S2. Two reviewers
(NFT and PB) independently searched MEDLINE,
EMBASE, the Cochrane Central, Cochrane database
for systematic reviews, Scopus, Web of Science, Goo-
gle Scholar. Additional pertinent citations were identi-
fied through bibliographies of retrieved studies.
Abstracts were imported into Mendeley and inde-
pendently screened by two reviewers NFT and PB ac-
cording to standard inclusion and exclusion criteria.
All studies identified for full manuscript review were
assessed independently by two reviewers (NFT and
PB) against inclusion criteria. Any discrepancies were
settled by a round table discussion and consultation
with the third reviewer (RP).
Selection criteria
We included case-control, cross-sectional, cohort studies
published between 1 January 1990 and 25 January 2019,
with primary purpose of evaluating Lassa fever test accur-
acy using any clinical specimen type. We also included
studies reporting original data from patient specimens in
all age groups, studies that reported the laboratory, clin-
ical/field evaluation of a diagnostic tests in humans; stud-
ies that reported the sensitivity and specificity with a
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reference standard. We excluded: articles in languages
other than English; conference abstracts, comments or re-
view papers; studies only reporting sensitivity or specificity
without reference standards; studies using commercially
prepared reference panels. We excluded studies not in-
volving human subjects.
Data extraction and quality assessment
Two reviewers (NFT and PS) independently extracted
data and reached agreement on the following variables
in the data extraction sheet: study author and year; study
location and design; patient age range; name and format
of the test; reference test; type and number of specimens
tested; type of evaluation (clinical/field vs laboratory);
sensitivity and specificity with 95% confidence intervals;
phase of infection during which sample were collected;
funding source and any reported conflict of interest. We
calculated the 95% confidence intervals for the studies
reporting only point estimates.
Study quality was evaluated using the Quality Assessment
of Diagnostic Accuracy Studies (QUADAS)-2 tool [18],
which evaluates risk of bias (patient selection, index test,
reference standard, and patient flow through) and applic-
ability concerns.
Data synthesis and analysis
We could not conduct a meta-analysis because: the
number of studies for each diagnostic test type was not
enough to pool together meaningful data; and the au-
thors were not consistent in the reference standards
used in the evaluation of the index tests. Therefore, we
carried out only a qualitative synthesis of the studies,
taking into consideration the weakness and strengths in
the methodologies of evaluation of the diagnostic tech-
nologies, that may have influenced the sensitivity and
specificity results obtained.
Results
Study selection and characteristics
A total of 1245 non-duplicate citations were identified,
and 26 full-text articles examined which identified 08
studies meeting pre-defined criteria (Fig. 1). Of the in-
cluded studies, 2 were conducted with patients from Si-
erra Leone only, 2 were conducted with patients from
Nigeria only, while in 4 studies, patients were enrolled
Fig. 1 PRISMA flow diagram showing databases searched, screening and inclusion of studies
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from multiple countries (Nigeria, Sierra Leone and
Guinea) and in two studies, samples from patients in
Germany were used (Table 1). In most of the studies
(05), samples were collected from patients suspected of
having Lassa fever. However, one study enrolled the
close contacts of patients suspected of having Lassa
fever, one study enrolled all patients with fever of un-
known origin and hemorrhage, one study enrolled
healthy adult blood donors and one study enrolled only
Lassa confirmed cases (Table 1).
Only two studies specified the age range of the pa-
tients from whom samples were taken. Studies were pro-
spective, cross-sectional or case-control, and
predominantly in the laboratory setting (Table 1). Only
01 study compared a rapid diagnostic test (RDT) against
an immunoassay and a molecular reference standard
(Table 2). This study was conducted in Sierra Leone and
involved the field of evaluation of the Recombinant
Lassa Virus RDT. Five studies compared immunoassays
against virus isolation or molecular reference standards,
while two studies compared molecular assays to virus
isolation as reference standard (Table 2).
Four (04) out of the six (06) studies that involved the
evaluation of antigen and/or antibody assay clearly
stated the phase of Lassa infection during which sam-
ples were collected from patients and tested. Most of
the samples were tested in the acute phase. One study
used convalescent samples (Table 3). Two studies did
not state their funding source (Table 3). Table 4 shows
the excluded full texts, the assays and the reasons for
exclusion.
Assessment of quality of studies
The results of the QUADAS-2 assessment for risk of
bias of each study, including summary figures, are
shown (Fig. 2). Bias in patient selection was generally at-
tributable to a case-control study design, or from enrol-
ment of highly selected participants such as only
patients with laboratory confirmed Lassa fever and
healthy adult blood donors. Risk of bias from the index
test was most commonly because they were conducted
and interpreted with the knowledge of the results of the
reference standard. There was an unclear risk of bias in
flow and timing because majority (75%) of studies did
not specify the exact time interval between performance
of the index and reference assay. In up to 65% of the
studies, there was high risk of bias in the reference
standard because virus culture was not used. However,
the applicability of the reference standard was of low
concern because the target condition that was defined
matched the review question.
Diagnostic accuracy of tests for Lassa
For rapid diagnostic test (RDT)
Only one study assessed the accuracy of a rapid test for
the diagnosis of Lassa fever [19]. This RDT evaluated is
the dipstick recombinant Lassa virus (ReLASV) assay
which is a lateral flow immunoassay based on paired
monoclonal antibodies to the Josiah strain of the Lassa
virus. This study was a prospective cohort study con-
ducted in Sierra Leone and involved the use of 451
serum and plasma samples from patients suspected of
having Lassa fever. The reference standards used were
Table 1 Characteristics of included studies: study population and design
Author and
reference
Year
Published
Journal Study Country Study population Study
design
Patient
Age Range
Boisen
et al. [19]
2018 Scientific Reports Sierra Leone Suspected Lassa fever patients and
their contacts
Prospective
cohort
not stated
Boisen
et al. [19]
2018 Scientific Reports Sierra Leone Suspected Lassa fever patients and
their contacts
Prospective
cohort
not stated
Bausch
et al. [20]
2000 Journal of Clinical Virology Sierra Leone and Guinea Suspected Lassa fever patients Prospective
cohort
not stated
Gabriel
et al. [21]
2017 PLOS Neglected Tropical
Diseases
Nigeria, Ghana and
Germany
Suspected Lassa fever patients Prospective
cohort
not stated
Ibekwe
et al. [22]
2012 Nigerian Medical Journal Nigeria Clinically diagnosed patients and
referred suspected patients
Case-
control
11–61
years
Meulen
et al. [23]
1998 Journal of Clinical
Microbiology
Guinea and Liberia and
Germany (Hamburg)
Patients with fever of unknown
origin and hemorrhage
Cross-
sectional
not stated
Emmerich
et al. [24]
2006 Journal of Clinical Virology Nigeria, Liberia, Sierra
Leone and Guinea
Healthy adult blood donors Cross-
sectional
18–53
Olschlager
et al. [25]
2010 Journal of Clinical
Microbiology
Liberia and Nigeria Laboratory confirmed Lassa patients Cross-
sectional
not stated
Trappier
et al. [26]
1993 American Journal of Tropical
Medicine and Hygiene
Sierra Leone Suspected Lassa fever patients Cross-
sectional
not stated
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Table 2 Characteristics of studies: test name, reference test, type of evaluation and diagnostic performance
Author Test Name Reference Test Type of
Samples
Number of
Samples Tested
Type of
evaluation
Sensitivity(95%
CI)
Specificity(95%
CI)
Boisen
et al
Recombinant Lassa Virus Rapid
Diagnostic Test (ReLASV RDT)
Nikisins qPCR Serum
and
plasma
451 Field
evaluation
91.2(75.2–97.7) 86(71.4–94.2)
ReLASV Ag ELISA Serum
and
plasma
451 Field
evaluation
94.8(81.3–99.1) 100(88.6–100)
Boisen
et al
Recombinant Lassa Virus Antigen
ELISA(ReLASV Ag ELISA)
Nikisins qPCR Serum
and
plasma
451 Field
evaluation
91.2(75.2–97.7) 86(71.4–94.2)
Bausch
et al
Combined ELISA Antigen/IgM
assay
Virus Isolation Serum 305 Laboratory 88(77–95) 90(88–91)
Indirect Immunofluorescent
antibody test
Virus Isolation Serum 305 Laboratory
validation
70(57–81) 88(85–90)
Gabriel
et al
IgM ELISA Standard RT-PCR Serum 270 Laboratory 31.1(25.6–37) 95.7(92.8–97.7)
Recombinant IgM/IgG ELISA Standard RT-PCR Serum 270 Laboratory 25.9(20.8–31.6) 100(98.2–100)
Ibekwe
et al
IgM ELISA Standard RT-PCR Serum 72 Laboratory 57(41.05–72.95) 77(63.06–90.94)
Meulen
et al.
IgM/IgG Immunoblot Indirect
Immunofluorescent
assay(IFA)
Serum 157 Laboratory 90.7(84.13–
97.27)
96.3(92.2–100)
Emmerich
et al
Reverse IgG ELISA IFA Serum 643 Laboratory 100(99–100) 99(98–100)
Olschlager
et al
GPC RT-PCR(Qiagen) Virus isolation Serum
and CSF
77 + (1CSF
sample)
Laboratory 100(99–100)
Trappier
et al
Conventional PCR Virus Isolation Serum 195 Laboratory 66(55–77) 78(69.5–84.5)
Table 3 Characteristics of included studies cont’d: phase of infection and funding source
Author
Last
Test Name Phase of infection Funding source
Boisen
et al
Recombinant Lassa Virus Rapid
Diagnostic Test (ReLASV RDT)
Acute phase NIH (National Institute for Health). Possible
conflict of interest with Viral Hemorrrhagic
fever Consortium.
Boisen
et al
Recombinant Lassa Virus Antigen ELISA
(ReLASV Ag ELISA)
NIH (National Institute for Health). Possible
conflict of interest with Viral Hemorrrhagic
fever Consortium.
Bausch
et al
Combined ELISA Antigen/IgM assay Acute phase. Convalescent samples collected but
data on testing not given.
American Association of Schools of Public
Health (AASPH) & Tulane University
Indirect Immunofluorescent antibody
test
Gabriel
et al
IgM ELISA Not clear European Fund for regional development
IgM/IgG ELISA
Ibekwe
et al
IgM ELISA Acute phase No funding source
Meulen
et al.
IgM/IgG Immunoblot Not clear Not stated
Emmerich
et al
Reverse IgG ELISA Convalescent samples (from survivors) Bundesamt f¨ur Wehrtechnik und
Beschaffung
Olschlager
et al
GPC RT-PCR(Qiagen) Not clear Bundesamt f¨ur Wehrtechnik und
Beschaffung
Trappier
et al
Conventional PCR Not clear Not stated
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Recombinant Antigen ELISA (Enzyme Linked Immuno-
sorbent Assay) and the Nikisins qPCR (quantitative
polymerase chain reaction). Compared with the ReLASV
antigen ELISA as the standard, the sensitivity and
specificity of the test were 94.1%(95%CI:78.9–99.0%)
and 83.7% (68.7–92.6%) respectively at temperatures
18–30 °C. Meanwhile, compared with the Nikisins
qPCR, the sensitivity and specificity were 91.2%(95%CI:
75.2–97.7) and 86%(95%CI:71.4–94.2) respectively at
temperatures 18–30 °C. Visual interpretation was pos-
sible within 15–25 min.
For immunoassays
Six studies evaluated the performance of immunoas-
says against different reference standards. Three of
the studies assessed the performance of combined
immunoassays [19–24]. The three combined immu-
noassays and their reference standards include: The
combined ELISA Antigen/IgM assay against virus
culture [20]; the combined IgM/IgG ELISA against
standard RT-PCR [21]; the combined IgM/IgG Im-
munoblot against Indirect Immunofluorescent
assay(IFA) [23].
Table 4 Excluded full texts and the reasons for exclusion
Study Assay Reason
1- Fukuma et al,
2011 [27]
Reverse Transcription LAMP No data on sensitivity and specificity. Just talks about assay development
1- Fukushi et al,
2012 [28]
Serological assays Review. No data on performance
3- Pang et al,
2014 [29]
Multiplex one step Real-Time Taqman qRT-
PCR
No data on sensitivity and specificity given. Not a lab or field evaluation.
4- Das et al,
2015 [30]
Multiplex PCR/LDR assay Not an evaluation. No data on sensitivity and specificity
5- Jones A et al,
2011 [31]
Handheld multiplex POC diagnostics No data on sensitivity and specificity
6- Trombley et al,
2010 [32]
RT-TaqMan PCR Not an evaluation study. No data on sensitivity and specificity
7- Drosten et al,
2002 [33]
SYBR-green real time RT-PCR Not a lab or field evaluation.
8- Bukbuk et al,
2014 [34]
Recombinant NP(rNP) IgG ELISA No data on sensitivity and specificity
9- Barber et al,
1990 [35]
Recombinant ELISA Not evaluated in humans. No data on sensitivity and specificity
10- Li et al,
2009 [36]
Fluorescent microbeads based multiplex
assay
No data on performance
11- Saijo et al,
2007 [37]
Ag-Capture ELISA No data on the performance
12- Salvato et al,
2018 [38]
Review
13- Satterly et al,
2016 [39]
Ag and IgM Capture(MAGPIX)
14- Olschlager et al,
2012 [40]
RT-PCR/hybridization assay No data on sensitivity and specificity
15- Vieth et al,
2007 [41]
RT-PCR Not an evaluation study
16- Leski et al,
2009 [42]
High Density Resequencing microarray No data on sensitivity and specificity.
17- O’Hearn et al,
2016 [43]
IgG(MAGPIX) No data on sensitivity and specificity
18- Demby et al,
1994 [44]
Standard RT-PCR Not an evaluation study
19- Sebba D et al,
2018 [45]
Multiplex POC test for Lassa, Ebola
and Malaria
None of the 276 clinical samples tested with the 3-plex assay were independently
tested for LASV.
20- Koehler et al,
2018 [46]
Highly Multiplex Broad Pathogen
detection assay
No data on sensitivity and specificity.
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The sensitivity of the combined ELISA Antigen/IgM
assay, the IgM/IgG ELISA, and the IgM/IgG immuno-
blot were 88%((95%CI:77–95), 25.9%(95%CI:20.8–31.6),
and 90.7%(95%CI:84.13–97.27) respectively. The specifi-
city of the combined ELISA Antigen/IgM assay, the
IgM/IgG ELISA, and the IgM/IgG immunoblot were
90%((95%CI:88–91), 100%(95%CI:98.2–100), and 96.3%(
95%CI: 92.2–100) respectively. In total, the studies in-
volving the evaluation of the combined immunoassays
used 732 serum samples.
Three studies evaluated a single immunoassay against
their reference standards as well. These single immuno-
assays include: The Recombinant Antigen ELISA assay
against the Nikisins qPCR [19]; the IgM ELISA against
RT-PCR [22]; and the Reverse IgG ELISA against IFA
[24]. The sensitivity of the Recombinant Ag ELISA, IgM
ELISA and Reverse IgG ELISA were 91.2%(95%CI:75.2–
97.7), 57%(95%CI:11.05–72.95) and 100%(95%CI:99–
100) respectively. The specificity of the Recombinant Ag
ELISA, IgM ELISA and Reverse IgG ELISA were
86%(95%CI:71.4–94.2), 77%(95%CI:63.06–90.94) and
99%(95%CI:98–100) respectively. The studies that evalu-
ated the single immunoassays used a total of 1166 serum
samples.
Gabriel et al [21] also evaluated the single IgM ELISA
assay alongside the evaluation of the combined IgM/IgG
assay. The sensitivity and specificity of the single IgM
assay against RT-PCR from this study were 31.1(95%CI:
25.6–37) and 95.7(95%CI: 92.8–97.7) respectively.
For molecular tests
Two studies reported the diagnostic performance of mo-
lecular assays [25, 26]. The molecular assays evaluated in
the laboratory were the Glycoprotein Precursor (GPC)
gene specific RT-PCR assay [25] and the conventional
PCR [26]. The GPC RT-PCR/2007 assay was validated
Fig. 2 Results of the quality assessment of studies using the QUADAS-2 tool
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with 77 serum samples and 1 CSF sample from patients
with laboratory- confirmed Lassa fever. Compared with
virus culture, the sensitivity of the assay was 100%(95%CI:
99–100). However, the sensitivity and specificity of the
conventional PCR assay were 66%(95%CI: 55–77) and
78%(95%CI:69.5–84.5) respectively. No study evaluated
the diagnostic performance of a multiplex assay for detec-
tion of many Lassa fever strains.
Discussion
Study findings
The findings from this first ever conducted systematic re-
view on the diagnostic performance of Lassa fever assays
show that of the studies included, the authors reported
different assays available for the detection of the Lassa
fever virus ranging from a point of care recombinant anti-
gen test, combined and single ELISA immunoassays and
molecular assays. The performance of combined immuno-
assays was higher than the single IgM ELISA assays, mak-
ing the use of single immunoassays of IgM ELISA
unsuitable for the screening of Lassa fever patients. Fur-
thermore, we found no study that evaluated and reported
the sensitivity and specificity of a multiplex assay for de-
tection of the different strains of Lassa virus in West
Africa.
Reference standards for Lassa fever diagnosis
In our study, we found that different reference standards
were used in the evaluation of diagnostic performance of
Lassa tests. This variation in reference standards ranging
from immunoassays to real time RT-PCR assays is a
clear indication that there is still no uniformly accepted
clinical reference standard besides virus culture. Even
though the high sensitivity and specificity of real time
RT-PCR assays make them suitable for this role [14],
there is need for more data on the clinical performance
of other molecular assays such as the RT-Taqman PCR
and the Nikisins qPCR. Immunoassays such as the anti-
gen capture ELISA assays may be unsuitable reference
standards due to the short period of antigenaemia dur-
ing a Lassa virus infection. There is also evidence to sug-
gest that the presence of IgM may either clear or mask
the detection of antigens for Lassa in blood [20].
Serum antigenaemia and antibody variation and the
performance of Lassa diagnostic tests
Typically, serum antigen levels peak during the first
week of illness with Lassa and are later replaced by IgM
during the second week [20]. IgG levels start rising dur-
ing the third week and remain positive even during the
convalescent period [20]. In our included studies, the au-
thors used samples collected from acutely ill patients,
convalescent patients or did not clearly state the phase
of infection during which samples were collected. It is
very important for researchers that are evaluating the
performance of serological assays to have this variation
in serum antigens and antibodies in mind because the
timing of testing can affect the performance of sero-
logical assays due to the variation in the serum antigen
and antibody levels.
The use of a point of care (POC) RDT for Lassa
The WHO call for rapid tests for Lassa has played a key
role to incentivize diagnostic development for Lassa [15].
Even though a definitive diagnosis of Lassa is only possible
in reference laboratories, point of care testing using RDTs
has the advantage of reducing delays in testing and treat-
ing, as well as facilitating a better understanding of the na-
ture of an outbreak [47]. Despite the urgent need for
RDTs, our study identified only one RDT under evalu-
ation: The Recombinant Lassa fever virus antigen test,
which is a lateral flow immunoassay against the Josiah
strain (lineage IV) of the Lassa fever virus. The perform-
ance of this assay was comparable to molecular tests such
as qPCR and RT-PCR at temperatures 18–30 °C. These re-
sults are very promising given that at such level of per-
formance, very few results will be false positives, making it
very useful in improving the case definition during an out-
break [14]. Furthermore, having such a highly performant
assay would greatly enhance appropriate patient enroll-
ment for vaccine and therapeutic clinical studies [14].
Despite the high performance of the RDT, there are
important concerns that may suggest the findings should
be interpreted with caution. Firstly, there is not enough
evidence to support the use of the Nikisins qPCR and
Recombinant Antigen ELISA as the gold standards. Sec-
ondly, the performance of the test above 30 °C was not
evaluated and given that Lassa fever occurs in humid
areas with high temperatures (approaching 40 °C or
more) such as in Northern Nigeria, these environmental
conditions should be taken into consideration if the test
is intended for use in such areas [5]. Thirdly, the assay
was limited to the Josiah strain of the Lassa virus. Taking
the diversity of the Lassa fever virus across West Africa
into consideration, more work is needed to design and
evaluate an RDT that can detect all Lassa strains. How-
ever, it has been reported that such a pan-Lassa virus
assay is currently being evaluated in Nigeria [31]. Future
efforts are also geared towards the development of a
point of care multiplex molecular assay using the SHER-
LOCK (Specific High Enzymatic Reporter Unlocking)
platform that can ensure even more precise testing with
earlier detection as compared with the lateral flow im-
munoassay [48]. For such a point of care multiplex
assay, more emphasis should be given to reducing the
cost, to ensure affordability and high uptake by the gov-
ernments of developing countries in West Africa.
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Antigen and antibody ELISA assays for detection of Lassa
For Serological assays to be useful in screening, etio-
logical diagnosis, and sero-epidemiological studies of
Lassa fever, they must be must be sensitive, specific and
reliable, since a misdiagnosis can misguide public health
interventions to control an outbreak and possibly trigger
panic in the population [14]. The sensitivity and specifi-
city of the single IgM ELISA assay evaluated were low
using the same reference standard in two different stud-
ies conducted in Nigeria. Gabriel et al didn’t clearly state
the phase of infection during which serum samples were
collected and tested, while Ibekwe et al clearly included
cases within 4 weeks of suspected infection. Even though
Ibekwe et al were precise about their inclusion criteria,
they did not stratify the number patients tested in each
week after recruitment. Since IgM antibodies become
detectable in the second week of infection [49], it is pos-
sible that the low performance of the IgM assay may
have been due to the inclusion and testing of mainly pa-
tients in the first week of infection.
To improve on the performance of single antibody
ELISA assays, Emmerich et al developed and evalu-
ated the reverse ELISA techniques [24]. The sensitiv-
ity and specificity of the reverse IgG ELISA using
Indirect Immunofluorescence assay (IFA) as gold
standard were as high as RT-PCR assays. This high
performance could be due to the modifications in the
design of the assay that ensure a more direct binding
of antigen-antibody complexes than in indirect ELISA
assays [24]. The high performance of the reverse
ELISA assays can be disputed based on the methodo-
logical flaws of the study. Using IFA as the gold
standard, and the use of serum samples from healthy
blood donors may suggest that the findings from the
study are conservative and should be interpreted with
care. Therefore, further studies evaluating the per-
formance of the reverse IgG assay with serum from
patients suspected of having Lassa at different stages
in their clinical presentation are needed to either con-
firm or refute the findings.
The use of recombinant antigen detection of Lassa
fever virus has improved on the development and ac-
cess of Lassa fever diagnostics by obviating the need
for BSL-4 facilities [28]. The Recombinant antigen
ELISA tests showed a high sensitivity comparable
with molecular testing. This higher performance of
antigen tests compared to antibody tests has been
linked to the high antigenemia in Lassa infection [50].
However, it should be noted that the short duration
of antigenemia means antigens can become undetect-
able despite high levels of viremia in Lassa fever pa-
tients, thereby markedly reducing the performance of
the antigen assays [14, 48]. Since antibodies have a
longer duration in blood, one way that has been
suggested to overcome this challenge has been to use
combined antigen/antibody ELISA assays. This could
explain why the combined antigen/IgM assay evalu-
ated by Bausch et al had a higher performance than
the single recombinant assay.
For molecular assays
Several molecular assays have been developed for
Lassa fever detection but only the performance of the
GPC RT-PCR have been evaluated recently. The per-
formance of the RT-PCR assay was very close to that
of the virus culture used as gold standard. This can
explain why RT-PCR assays have been used as clinical
standard for in some Lassa fever studies [14]. The
stark difference in sensitivity between conventional
PCR and gene specific RT-PCR can be due to the
high variability of the Lassa virus which limited the
ability of the conventional PCR to reliably detect all
strains. With the gene specific RT-PCR, a revised
protocol which considered the 62 S RNA (ribonucleic
acid) sequence from all Lassa endemic countries was
used. This greatly improved the sensitivity of the RT-
PCR. The main caveat of the study evaluating the
performance of the gene specific RT-PCR is the small
sample size used in the laboratory evaluation. Studies
that are conducted in the field with larger sample
sizes will be needed to confirm the findings. RT-PCR
assays are widely used in screening samples and in
reference laboratory settings in the diagnosis of Lassa,
but the level of sophistication and training limit their
use in peripheral health care settings. To overcome
this limitation, a new RT-LAMP is currently under
development, but a field evaluation is still yet to be
carried out to provide data on its performance [27].
The main challenge with nucleic acid detection assays
for Lassa is the genetic diversity which may have a pro-
found negative effect on their performance even if there
is minimal variations in just one primer [51]. However,
by re-designing the assays after identification of mis-
matches, the performance of RT-PCR assays has been
optimized. Furthermore, multiplex assays such as the
RT-Taqman PCR and the PCR/LDR assays that detect
several strains of Lassa alone or in combination with en-
zyme hybridization, as well as many other hemorrhagic
viruses have been developed [29, 30]. Even though none
of these multiplex assays have been evaluated in the
field, their use in epidemic response will be crucial in
screening patients in areas where many hemorrhagic
fever viruses can occur and in which many patients may
present with fever of unknown origin.
Strengths and limitations
Our systematic review has several strengths and some
limitations. Many databases were searched using a
Takah et al. BMC Infectious Diseases          (2019) 19:647 Page 9 of 11
clearly defined search strategy. There was independent
search, screening and extraction of data from articles,
thereby reducing the bias in the selection of articles for
inclusion. We also assessed the quality of included stud-
ies, through which weaknesses in the methodology of in-
cluded studies were identified so that lessons can be
learnt by other investigators as they design and conduct
any future diagnostic studies for Lassa. The main limita-
tion we could identify in our study was that we targeted
only studies evaluating diagnostics for humans even
though Lassa fever is a zoonotic infection [7]. Therefore,
our study does not provide any information on the use
of diagnostics for Lassa in animals. Despite this limita-
tion, our study is the first of its kind involving the review
of the evidence on a clearly formulated research ques-
tion using systematic and explicit methods to identify,
select and critically appraise relevant primary research,
and to extract data from the studies on Lassa fever diag-
nostics. This high level of transparency and robustness
suggests the level of bias is very low.
Conclusion
Lassa fever has assays for antigenaemia, IgM, IgG and
PCR detection. The RDT we identified in our study, re-
portedly performed well but more data are needed from
other countries and at temperatures above 30 °C. Com-
bined immunoassays perform better than the single IgM
immunoassays. More data are needed to establish a clin-
ical reference standard for Lassa fever diagnosis. Multi-
plex and pan-Lassa assays are needed for Lassa. More
well conducted field and laboratory studies with a clear
description of the patient/sample flow and timing are
needed in future.
Additional files
Additional file 1: Table S1. Medline search strategy. (DOCX 15 kb)
Additional file 2: Table S2. Embase search strategy. (DOCX 13 kb)
Abbreviations
Ag: Antigen; ELISA: Enzyme Linked Immunosorbent Assay; IFA: Indirect
Immunofluorescent Assay; LAMP: Loop-mediated Isothermal Amplification;
qPCR: Quantitative PCR; QUADAS: Quality Assessment tool for Diagnostic
Accuracy Studies; RDT: Rapid diagnostic test; ReELISA: Recombinant Enzyme
Linked Immunosorbent Assay; RNA: Ribonucleic acid; RT-PCR: Real Time
Polymerase Chain Reaction
Acknowledgements
We would like to acknowledge the assistance of the Librarian of the London
School of Hygiene and Tropical Medicine in the developing the search
strategy for this study.
Authors’ contributions
NFT and PB designed the study, with input from RP in building search
algorithm and retrieving articles. All authors contributed to study
optimization. NFT, PB and PS identified and extracted data. NFT wrote the
manuscript with input from PB, PS and RP. All authors read and approved
the final manuscript.
Funding
This research was funded by EPSRC IRC in Early-Warning Sensing Systems for
Infectious Diseases (i-sense) EP/K031953/1. The funding body had no role in
the study design, collection, analysis, interpretation of data and in writing
the manuscript.
Availability of data and materials
All the data used in this study have provided in the tables submitted.
Ethics approval and consent to participate
Not applicable.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Author details
1International Diagnostics Centre Africa, Addis Ababa, Ethiopia. 2London
Centre for Nanotechnology, University College London, London, UK.
3International Diagnostics Centre, Clinical Research Department, London
School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT,
UK.
Received: 14 February 2019 Accepted: 30 June 2019
References
1. Hallam HJ, Hallam S, Rodriguez SE, Barrett ADT, Beasley DWC, Chua A, et al.
Baseline mapping of Lassa fever virology, epidemiology and vaccine
research and development. NPJ Vaccines. 2018;3:11.
2. Richmond JK, Baglole DJ. Lassa fever: epidemiology, clinical features, and
social consequences. BMJ. 2003;327(7426):1271–5.
3. World Health Organization(WHO). The WHO research and development
blueprint:list of priority diseases. https://www.who.int/medicines/ebola-
treatment/WHO-list-of-top-emerging-diseases/en/. Accessed 10 Dec 2015.
4. Ogbu O, Ajuluchukwu E, Uneke CJ. Lassa fever in west African sub-region:
an overview. J Vector Borne Dis. 2007;44:1–11.
5. The Lancet Infectious Diseases. Lassa fever and global health security.
Lancet Infect Dis. 2018;18:357.
6. World Health Organisation(WHO). Emergencies preparedness, response.
Lassa fever-Nigeria. 2019. https://www.who.int/csr/don/14-february-2019-
lassa-fever-nigeria/en/.
7. Agbonlahor DE, Erah A, Agba IM, Oviasogie FE, Ehiaghe AF, Wankasi M,
et al. Prevalence of Lassa virus among rodents trapped in three South-
South States of Nigeria. J Vector Borne Dis. 2017;54(2):146–50.
8. Effiong EB. Epidemiology and control of Lassa fever. Inter Ped Dent
Open Acc J. 2018;1(4):IPDOAJ.MS.ID.000116.
9. Bausch DG, Hadi CM, Khan SH, Lertora JJ. Review of the literature and
proposed guidelines for the use of oral ribavirin as postexposure
prophylaxis for Lassa fever. Clin Infect Dis. 2010;51:1435–41.
10. Hamblion EL, Raftery P, Wendland A, Dweh E, Williams GS, George
RNC, et al. The challenges of detecting and responding to a Lassa
fever outbreak in an Ebola-affected setting. Int J Infect Dis. 2018;66:
65–73.
11. Fatiregun AA, Isere EE. Epidemic preparedness and management: a guide
on Lassa fever outbreak preparedness plan. Niger Med J. 2017;58(1):1–6.
12. Yun NE, Walker DH. Pathogenesis of Lassa fever. Viruses. 2012;4:2031–48.
13. Lassa Fever Research and Development ( R & D ) Roadmap. 2018;1–18.
https://www.who.int/blueprint/priority-diseases/key-action/LassaFever_
Draft_Roadmap_publiccomment_MAY2018.pdf?ua=1.
14. Raabe V, Koehler J. Laboratory diagnosis of Lassa fever. J Clin Microbiol.
2017;55:1629–37.
15. World Health Organization(WHO). The WHO calls for early diagnostic tests
for Lassa. https://www.who.int/emergencies/diseases/lassa-fever/early-
diagnostic-lassa-fever/en. Accessed Apr 2016
16. Brangel P, Fongwen N. International prospective register of systematic
reviews diagnostic accuracy of tests to detect lassa fever virus : a systematic
review of the literature and meta-analysis; 2018. p. 1–3. http://www.crd.york.
ac.uk/PROSPERO/display_record.php?ID=CRD42018091585
Takah et al. BMC Infectious Diseases          (2019) 19:647 Page 10 of 11
17. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for
systematic reviews and meta-analyses : the Prisma statement. Ann Intern
Med. 2009;151(4):264–9.
18. Whiting PF, Rutjes AWS, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al.
QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy
studies. Ann Intern Med. 2011;155(8):529–36.
19. Boisen ML, Hartnett JN, Shaffer JG, Goba A, Momoh M, Sandi JD, et al. Field
validation of recombinant antigen immunoassays for diagnosis of Lassa
fever. Sci Rep. 2018;8:5939.
20. Bausch DG, Rollin PE, Demby AH, Coulibaly M, Kanu J, Conteh AS, et al.
Diagnosis and clinical virology of Lassa fever as evaluated by enzyme-linked
immunosorbent assay , indirect fluorescent- antibody test , and virus
isolation. J Clin Microbiol. 2000;38:2670–7.
21. Gabriel M, Adomeh DI, Ehimuan J, Oyakhilome J, Omomoh EO, Ighodalo Y,
et al. Development and evaluation of antibody-capture immunoassays for
detection of Lassa virus nucleoprotein-specific immunoglobulin M and G.
PLoS Negl Trop Dis. 2018;12(3):e0006361.
22. Ibekwe TS, Nwegbu MM, Asogun D, Adomeh DI, Okokhere PO. The
sensitivity and specificity of Lassa virus IgM by ELISA as screening tool at
early phase of Lassa fever infection. Niger Med J. 2012;53:196–9.
23. Ter Meulen J, Koulemou K, Wittekindt T, Windisch K, Strigl S, Conde S, et al.
Detection of Lassa virus antinucleoprotein immunoglobulin G (IgG) and IgM
antibodies by a simple recombinant immunoblot assay for field use. J Clin
Microbiol. 1998;36:3143–8.
24. Emmerich P, Thome-Bolduan C, Drosten C, Gunther S, Ban E, Sawinsky I, et
al. Reverse ELISA for IgG and IgM antibodies to detect Lassa virus infections
in Africa. J Clin Virol. 2006;37:277–81.
25. Ölschläger S, Lelke M, Emmerich P, Panning M, Drosten C, Hass M, et al.
Improved detection of Lassa virus by reverse transcription-PCR targeting the
5′ region of S RNA. J Clin Microbiol. 2010;48:2009–13.
26. Trappier SG, Conaty AL, Farrar BB, Auperin DD, McCormick JB, Fischer-Hoch
SP. Evaluation of the polymerase chain reaction for diagnosis of Lassa virus
infection. Am J Trop Med Hyg. 1993;49(2):214–21.
27. Fukuma A, Kurosaki Y, Morikawa Y, Grolla A, Feldmann H, Yasuda J. Rapid
detection of Lassa virus by reverse transcription-loop-mediated isothermal
amplification. Microbiol Immunol. 2011;55(1):44–50.
28. Fukushi S, Tani H, Yoshikawa T, Saijo M, Morikawa S, F S, et al. Serological
assays based on recombinant viral proteins for the diagnosis of arenavirus
hemorrhagic fevers. Viruses. 2012;4(10):2097–114.
29. Pang Z, Li A, Li J, Qu J, He C, Zhang S, et al. Comprehensive multiplex one-
step real-time TaqMan qRT-PCR assays for detection and quantification of
hemorrhagic fever viruses. PLoS One. 2014;9:e95635.
30. Das S, Rundell MS, Mirza AH, Pingle MR, Shigyo K, Garrison AR, et al. A
multiplex PCR/LDR assay for the simultaneous identification of category a
infectious pathogens: agents of viral hemorrhagic fever and Variola virus.
PLoS One. 2015;10:e0138484.
31. Jones A, Boisen M, Radtkey R, Blidner R, Goba A, Pitts K, et al. Development
of a handheld multiplex point of care diagnostic for differentiation of Lassa
fever, Dengue fever and Ebola Hemorrhagic Fever. 2011. https://www.nano.
com/downloads/Nanomix_AACC_poster_Abstract.pdf.
32. Trombley AR, Wachter L, Garrison J, Buckley-Beason VA, Jahrling J, Hensley
LE, et al. Comprehensive panel of real-time TaqMan polymerase chain
reaction assays for detection and absolute quantification of filoviruses,
arenaviruses, and New World hantaviruses. Am J Trop Med Hyg. 2010;82:
954–60.
33. Drosten C, Gottig S, Schilling S, Asper M, Panning M, Schmitz H, et al. Rapid
detection and quantification of RNA of Ebola and Marburg viruses, Lassa
virus, Crimean-Congo hemorrhagic fever virus, Rift Valley fever virus, dengue
virus, and yellow fever virus by real-time reverse transcription-PCR. J Clin
Microbiol 2002;40(7):2323-30.
34. Bukbuk DN, Fukushi S, Tani H, Yoshikawa T, Taniguchi S, Iha K, et al.
Development and validation of serological assays for viral hemorrhagic
fevers and determination of the prevalence of Rift Valley fever in Borno
State, Nigeria. Trans R Soc Trop Med Hyg; 2014;108:768–73.
35. Barber GN, Clegg JC, Lloyd G, G.N. B, J.C.S. C. Expression of the Lassa virus
nucleocapsid protein in insect cells infected with a recombinant
baculovirus: application to diagnostic assays for Lassa virus infection. J Gen
Virol 1990;71 ( Pt 1):19-28.
36. Li J, Zhang S, Zhang Q, Liu Q, Wei Y, Li C, et al. Fluorescent microbeads-
based multiplex detection of IgM antibodies to pathogens caused viral
hemorrhagic fever. Chin J Exper Clin Virol 2009;23:149–51.
37. Saijo M, Georges-Courbot MC, Marianeau P, Romanowski V, Fukushi S,
Mizutani T, et al. Development of recombinant nucleoprotein-based
diagnostic systems for lassa fever. Clin Vaccine Immunol 2007 ;14(9):1182-9.
38. Salvato MS, Lukashevich IS, Medina-Moreno S, Zapata JC. Diagnostics for
Lassa Fever: Detecting Host Antibody Responses. Methods Mol Biol 2018;
1604:79–88.
39. Satterly NG, Voorhees MA, Ames AD, Schoepp RJ. Comparison of MagPix
Assays and Enzyme-Linked Immunosorbent Assay for Detection of
Hemorrhagic Fever Viruses. J Clin Microbiol 2017;55:68–78.
40. Olschlager S, Gunther S. Rapid and specific detection of Lassa virus by
reverse transcription-PCR coupled with oligonucleotide array hybridization. J
Clin Microbiol 2012;50:2496–9.
41. Vieth S, Drosten C, Lenz O, Vincent M, Omilabu S, Hass M, et al. RT-PCR
assay for detection of Lassa virus and related Old World arenaviruses
targeting the L gene. Trans R Soc Trop Med Hyg 2007;101:1253–64.
42. Leski TA, Lin B, Malanoski AP, Wang Z, Long NC, Meador CE, et al. Testing
and validation of high density resequencing microarray for broad range
biothreat agents detection. PloS one 2009;4:e6569.
43. O'Hearn AE, Voorhees MA Fetterer DP, Wauquier N, Coomber MR, Bangura
J, et al. Serosurveillance of viral pathogens circulating in West Africa. Virol J
2016 ;13(1):163.
44. Demby AH, Chamberlain J, Brown DW, Clegg CS. Early diagnosis of Lassa
fever by reverse transcription-PCR. J Clin Microbiol 1994;32:2898–903.
45. Sebba D, Lastovich AG, Kuroda M, Fallows E, Johnson J, Ahouidi A, et al. A
point-of-care diagnostic for differentiating Ebola from endemic febrile
diseases. Sci Transl Med 2018;10(471).
46. Koehler JW, Douglas CE, Minogue TD. A highly multiplexed broad pathogen
detection assay for infectious disease diagnostics. PLoS Negl Trop Dis 2018;
12:e0006889.
47. Dhillon RS, Srikrishna D, Garry RF. Early detection of Lassa fever: the need
for point-of-care diagnostics. Lancet Infect Dis. 2018;18:601–2.
48. Gootenberg JS, Abudayyeh OO, Kellner MJ, Joung J, Collins JJ, Zhang F.
Multiplexed and portable nucleic acid detection platform with Cas13,
Cas12a, and Csm6. Science. 2018;360(6387):439–44.
49. Johnson KM, McCormick JB, Webb PA, Smith ES, Elliott LH, King IJ. Clinical
virology of Lassa fever in hospitalized patients. J Infect Dis. 1987;155(3):456–
64.
50. Niklasson BS, Jahrling PB, Peters CJ. Detection of Lassa virus antigens and
Lassa virus-specific immunoglobulins G and M by enzyme-linked
immunosorbent assay. J Clin Microbiol. 1984;20:239–44.
51. Stadhouders R, Pas SD, Anber J, Voermans J, Mes THM, Schutten M. The
effect of primer-template mismatches on the detection and quantification
of nucleic acids using the 5′ nuclease assay. J Mol Diagn. 2010;12(1):109–17.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Takah et al. BMC Infectious Diseases          (2019) 19:647 Page 11 of 11
